Table 1.
Patient demographics and study outcomes
| 001 | 002 | 003 | |
|---|---|---|---|
| Age | 81 years | 53 years | 35 years |
| Sex | Male | Male | Male |
| Date of first surgery (resection) | 9/26/2014 (subtotal) | 11/20/2015 (gross total) | 3/29/2012 (gross total) |
| Pathology | GBM | GBM | GBM |
| MGMT status | Hypermethylated | Unmethylated | Unmethylated |
| IDH-1 (R132H) | Negative | Negative | Positive |
| PFS from first surgery | 21 months | 9 months | 54 months |
| KPS at recurrence | 70 | 80 | 90 |
| Ribociclib treatment prior to surgery | 8 days | 12 days | 14 days |
| Date of second surgery (resection) | 8/16/2016 (subtotal) | 9/7/2016 (gross total) | 10/19/2016 (subtotal) |
| Pathology | Recurrent GBM | Recurrent GBM | Recurrent GBM |
| PFS from start of Ribociclib | 2 months | 5 months | 2 months |
| OS from second surgery | 10 months | 19 months | 12 months |
| OS from first surgery | 32 months | 28 months | 66 months |
GBM glioblastoma, MGMT methyl-guanine-methyl-transferase, IDH isocitrate dehydrogenase, PFS progression-free- survival, KPS Karnofsky performance scale score, OS overall survival